View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Sponsored by SHL

Injecting High-Volume, High-Viscosity Drugs

Free White Paper

Injecting High-Volume, High-Viscosity Drugs

By SHL

Injecting High-Volume, High-Viscosity Drugs

By SHL
Enter your details to receive the free paper:

SHL has extensive experience in the parenteral arena. In this article, SHL details its latest offerings in the world of biologics, as well as its partnership with speciality digital healthcare start-up QuiO to develop injectables in the connected healthcare space.

With autoinjectors delivering higher doses of proteins subcutaneously, there is the major consideration of injection duration. A duration of 10-15 seconds has historically been regarded as the maximum acceptable threshold for autoinjection. Patients typically prefer to not hold a device in place for any longer.

The complex molecular structure of biologics also poses a technical challenge. Biologics have a propensity towards destabilising or aggregating in a prefilled syringe or other primary packaging over the course of their shelf life.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology